San Diego, USA
Dustin joined Datamonitor Healthcare in the summer of 2015. One of the highlights of his role has been analyzing the development of novel therapies from the early pre-clinical and clinical phases, through final approval and marketing authorization. Having been involved in cancer research as a graduate student, Dustin is fascinated by new compounds or mechanisms of action and their impact on the oncology treatment space, both from a clinical and commercial viewpoint.He has a Bachelor of Science in Applied and Computational Mathematics and a PhD in Biological Sciences, both from the University of California, Irvine.
Dustin Writes For
By Dustin Phan 12 Jan 2017
Accelerated approval of Keytruda in combination with chemotherapy for NSCLC could serve to strengthen the drug’s first-line lead by expanding the eligible patient population to include all PD-L1 expression levels.
Topics Research wire
By Dustin Phan 21 Jul 2015
Takeda announced the submission of a New Drug Application for ixazomib, the first orally administered proteasome inhibitor for multiple myeloma. On 14 July 2015, Takeda announced the
Topics Clinical trial optimization
30 Nov 2015
11 Nov 2015